Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Gabrovo – page 7

234 clinical trials in Gabrovo, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gabrovo at a glance
234
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

234 trials in Gabrovo

Open in trial search

Colitis ulcerative+1

Recruiting

Study of MT-501 in patients with active Crohn's Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:MT-201
  • Sponsor:Mirador Therapeutics Inc.

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Prostate cancer

Recruiting

Study Comparing Rezvilutamide and Bicalutamide with Hormone Therapy for Patients with Advanced Prostate Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 52 cities in Bulgaria

Clinical research in Gabrovo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, lung cancer, and bladder cancer. Research encompasses both targeted therapies and combination treatments.

  • Metastatic breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Prostate cancer interventions
  • Bladder cancer treatments

Special emphasis on developing targeted therapies for specific genetic mutations and combinations with immunotherapy.

02 Respiratory Medicine

Comprehensive research into respiratory conditions, with particular focus on chronic diseases and their management through innovative therapeutic approaches.

  • Asthma management studies
  • COPD treatment evaluations
  • Maintenance therapy optimization

Trials evaluate both single and combination therapies for improving lung function and quality of life.

03 Dermatology Studies

Advanced research in chronic skin conditions, investigating new therapeutic options for various dermatological disorders.

  • Plaque psoriasis treatments
  • Atopic dermatitis therapies
  • Long-term safety evaluations

Focus on developing both topical and systemic treatments for moderate to severe cases.

04 Cardiovascular Research

Innovative studies addressing heart conditions and related metabolic disorders, including new approaches to managing cholesterol and heart failure.

  • Heart failure treatments
  • Cholesterol management
  • Hypertriglyceridemia therapies

Emphasis on both preserved and reduced ejection fraction heart failure treatments.

05 Infectious Diseases

Research focusing on viral infections and preventive medicine, including vaccine development and infection management.

  • Influenza vaccine studies
  • Varicella vaccination
  • Urinary tract infection treatments

Special attention to vaccine safety and efficacy in various age groups.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.